Excerpts

All cancer types showed a trend of overall increased resistance in 3D compared to 2D in vitro tumour cultures.

While pathway activity scores between quadrant samples of a single block, and between blocks of one PT showed highly significant correlations, correlations decreased between PT and LN metastases and significance was lost.

Upon comparison of all CAFs with all NFs, the two proteins αSMA and CAV1 showed a clear trend towards increased abundance in CAFs, while CD90 was significantly enriched in NFs.

They also suggest that FUS-TB may detect higher rates of csCPa compared to COG-TB, with results approaching significance.

Borderline significant associations were found for these variables in the Trajectory-2 vs.

Comparison of cancer to controls was highly significant for all markers in all fractions; however, urine sediment performed best to detect CIN3.

These cumulative incidence curves demonstrated a clear trend between a higher comorbidity count and increasing other-cause mortality in all three age groups. 4.

miR-182-5p showed a trend towards correlation with TTMOTB. miR-20a-5p, miR-335-3p, miR-27a-3p, and miR-23a-3p were clearly not correlated to TTMOTB, thus their effect might be specific for the development of BM.

p -values between 0.05 and 0.15 were considered indicative of a statistical trend.

Furthermore, unlike targeting either KDM4A or KDM4B alone, dual targeting led to a highly significant increase in Caspase activity indicative of apoptosis in these cells ( Figure 6 B and Figure S10 ), suggesting that these two demethylase family members have distinct roles in RMS cell growth and that combined inhibition of both KDM4A and KDM4B is required in RMS to induce apoptosis and reduce the potential for resistance to KDM4 subfamily targeted therapies. 4.

combo at D24: p = 0.101 as determined with the Mann–Whitney one tail test), we showed a trend towards a potentiated effect with the murlentamab/pembrolizumab combo-therapy ( Figure 5 E).

The IELSG32-trial showed no beneficial effect on CR rates, progression-free and overall survival by solely adding rituximab to a high-dose methotrexate-based chemotherapy regimen, although the difference in progression-free survival showed a trend of borderline significance.

The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes.

We have shown that an elevation of cell-bound CA125 is markedly significant on T cells and NK cells, and significant on B cells as well as all PBMCs together.

While age itself did not have an influence on the prognosis, PRKCA overexpression status showed a highly significant association with poor OS and DFS within the young OTSCC subgroup ( Figure 2 ).

Preliminary studies showed a trend [ 166 ] or clear evidence [ 156 , 160 ] of the prognostic value of CTC detection even in sarcoma.

We would emphasize that this observation should be interpreted with great care because the patients are few and the difference reached only borderline significance, but previous studies also suggest that ATRA therapy is less effective in patients with NPM1 wt [ 91 ].

Patients with high PD-L1 expression on IC showed a trend for improved survival as assessed by IC area 25% alone ( Figure 2 D; not significant in multivariable survival models) and significantly improved DSS (5-year DSS rate: 61%; HR mult = 0.44 [95%-CI = 0.27–0.72]) and DFS (5-year DFS rate: 58%; HR mult = 0.42 [95%-CI = 0.26–0.68]) as assessed by Ventana IC5% ( Figure 2 E).

This is also reflected by the borderline significance of PD-L1 expression in multi-variable adjusted survival analyses in this study [ 36 ].

Additionally, the subset of the BRAF mutated melanoma cohort of the cancer genome atlas (TCGA) harboring an EZH2 silent mutation, showed a highly significant enforced miR-129-5p expression compared to BRAF mutated melanoma patients with EZH2 wildtype ( Figure 3 E).

Our result showed an increasing trend of CTLA-4 in tissues and cell lines.

Analyses revealed that the pretreatment concentration of pHPV showed a trend towards correlation between stage and level of pHPV, in line with previous observations in other tumor types, and from smaller observations in SCCA [ 18 , 23 ].

Therefore, we confirmed a significantly increased MOS mRNA in KCCux1p110 mice compared to control mice and an apparent trend compared to KC mice ( Figure S5C ).

Importantly, combinations are suggested to attenuate possible associated adverse side effects by decreasing therapy dosage, highly significant for pediatric patients.

Although bevacizumab is known to increase bleeding risk, data presented from the IMbrave150 study do not show a clear trend regarding an increased risk of bleeding.